ストックスクリーナーアプリを入手
0.369
3.36%
0.012
アフターアワーズ：
.36
-0.009
-2.44%
前日終値:
$0.357
開ける：
$0.355
24時間の取引高:
78,246
Relative Volume:
0.79
時価総額：
$13.18M
収益：
$45.91M
当期純損益:
$-4.62M
株価収益率:
-2.632
EPS:
-0.1402
ネットキャッシュフロー:
$-21.51M
1週間 パフォーマンス:
-1.76%
1か月 パフォーマンス:
-12.14%
6か月 パフォーマンス:
-48.68%
1年 パフォーマンス:
-65.19%
1日の値動き範囲:
$0.355
$0.3751
1週間の範囲:
$0.346
$0.393
52週間の値動き範囲:
$0.3442
$1.50
Equillium Inc Stock (EQ) Company Profile
EQ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.369 | 13.42M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2021-10-29 | 再開されました | Stifel | Buy |
| 2021-09-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-10 | 再開されました | Stifel | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Equillium Inc (EQ) 最新ニュース
Equillium (NASDAQ:EQ) Trading Down 6.1% – Time to Sell? - Defense World
Equillium expands equity incentive plan by 1.78 million shares - Investing.com Canada
Equillium Holds Annual Stockholders Meeting on Key Proposals - TipRanks
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - BioSpace
Renaissance Technologies LLC Sells 59,773 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium stock touches 52-week low at $0.52 amid market challenges - MSN
Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - BioSpace
FDA declines itolizumab accelerated approval, says Equillium - The Pharma Letter
Equillium shares fall following FDA feedback By Investing.com - Investing.com India
Equillium shares fall following FDA feedback - Investing.com Australia
Equillium Announces Feedback from the U.S. Food and Drug Adminis - GuruFocus
Equillium (EQ) Faces Setback as FDA Declines Accelerated Approva - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval By Investing.com - Investing.com Canada
Equillium (EQ) Faces FDA Setback for Itolizumab in Graft-versus-Host Disease Treatment | EQ Stock News - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval - Investing.com
Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
Equillium (NASDAQ:EQ) Shares Down 3.7% – Here’s Why - Defense World
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st
Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World
Leerink Partners Reaffirms “Market Perform” Rating for Equillium (NASDAQ:EQ) - Defense World
The week in pharma: action, reaction and insight – week to March 28 - The Pharma Letter
Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World
Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq
Equillium stock tumbles on Phase 3 study results By Investing.com - Investing.com India
Equillium stock tumbles on Phase 3 study results - Investing.com
Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace
Equillium Reports 2024 Financials and Clinical Milestones - TipRanks
Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com
Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa
Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia
Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter
Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener
Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com
Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe
Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - Stock Titan
Equillium Inc (EQ) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):